AmtixBio

본문 바로가기

팝업레이어 알림

팝업레이어 알림이 없습니다.
사이트 내 전체검색
KOR
ENG
KOR
ENG
AmtixBio

Global Company Developing Innovative New Drugs

To build a sustainable response to microbial infectious and related inflammatory diseases, AmtixBio develops innovative new drugs based on microbial virulence targets and drug properties.

AmtixBio

Essential/Social/Global Company

AmtixBio collectively address the global challenge of infectious diseases through complementary approaches: building sustainable response systems, improving access in underserved areas, and developing innovative treatments for widespread commercialization

AmtixBio

A global pharmaceutical company developing innovative new drugs to overcome microbial infectious diseases and related diseases

Pipeline

AmtixBio develops innovative drugs based on virulence factors based microbial infection targets to build sustainable responsiveness to microbial infectious diseases and related inflammatory diseases

View more

  • 01. ATB1651

    Antifungal Onychomycosis / Dermatophytosis

  • 02. ATB6013

    Antifungal Mucormycosis / Aspergillosis

  • 03. ATC0001

    Antifungal Multi-drug-resistant candidiasis

  • 04. ATB1606

    Anti-inflammatory Atopic Dermatitis / Psoriasis, Asthma

  • 05. SAMH

    Biocompatible Materials Next Gen. Dermal filler / Drug Delivery System(DDS)

회원로그인

회원가입
Headquarters/Laboratory:
Room A-801,802,826,828,829,830, Misa-daero 540, Hanam-si, Gyeonggi-do
GMP:
Room 901,902,903,904,1304, Hanam-daero 947 Hanam-si, Gyeonggi-do
Branch:
Room 606, 2-dong, 61, Madeul-ro 13-gil, Dobong-gu, Seoul (Chang-dong, Seed Cube Chang-dong)
Copyright (c) AmtixBio Corp, All Rights Reserved.